A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib

The second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and ceritinib are standard treatment options for patients with non–small cell lung cancer (NSCLC) positive for ALK fusion genes. However, almost all patients eventually develop resistance to these drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Makuuchi, Yosuke, Hayashi, Hidetoshi, Haratani, Koji, Tanizaki, Junko, Tanaka, Kaoru, Takeda, Masayuki, Sakai, Kazuko, Shimizu, Shigeki, Ito, Akihiko, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955410/
https://www.ncbi.nlm.nih.gov/pubmed/29796191
http://dx.doi.org/10.18632/oncotarget.25143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955410/
https://www.ncbi.nlm.nih.gov/pubmed/29796191
http://dx.doi.org/10.18632/oncotarget.25143

Ejemplares similares